InstitutionMD Anderson
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 Apr 20; 14(641):eabm6420. PMID: 35442707.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022 Jan 07; 30:100514. PMID: 35051703.
      Citations:    Fields:    
    3. Rice D, Rodriguez-Restrepo A, Mena G, Cata J, Thall P, Milton D, Correa A, Woodard T, Antonoff M, Hofstetter W, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A, Mehran R. Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Ann Surg. 2021 12 01; 274(6):1099-1106. PMID: 32229762.
      Citations: 4     Fields:    Translation:Humans
    4. Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol. 2021; 5. PMID: 34805718.
      Citations:    Fields:    Translation:Humans
    5. Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med. 2021 10 30; 40(24):5199-5217. PMID: 34636054.
      Citations:    Fields:    
    6. Msaouel P, Lee J, Thall PF. Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers (Basel). 2021 Jun 01; 13(11). PMID: 34205968.
    7. Ghia AJ, Guha-Thakurta N, Song J, Thall P, Briere TM, Settle SH, Sharp HJ, Li J, McAleer M, Chang EL, Tatsui CE, Brown PD, Rhines LD. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously irradiated metastatic epidural spinal cord compression. N Am Spine Soc J. 2021 Jun; 6:100066. PMID: 35141631.
    8. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719. PMID: 33929874.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    9. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol. 2021; 12:675679. PMID: 33995420.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    10. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. medRxiv. 2021 Mar 10. PMID: 33758890.
    11. Park Y, Liu S, Thall PF, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics. 2022 Mar; 78(1):60-71. PMID: 33438761.
      Citations: 2     Fields:    Translation:Humans
    12. Dahlstrom KR, Song J, Thall PF, Fuller CD, Hutcheson KA, Johnson FM, Gunn GB, Phan J, Frank SJ, Morrison WH, Ferrarotto R, Rosenthal DI, Sturgis EM, Garden AS. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237. PMID: 33306202.
      Citations:    Fields:    Translation:Humans
    13. Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys. 2020 12 01; 108(5):1399-1400. PMID: 33427657.
      Citations: 3     Fields:    
    14. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020 11 10; 4(21):5580-5588. PMID: 33170934.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    15. Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, Mandrekar SJ. Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. Cancers (Basel). 2020 Nov 04; 12(11). PMID: 33158080.
      Citations: 4     
    16. Chapple AG, Thall PF. Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteria. Contemp Clin Trials. 2020 10; 97:106099. PMID: 32822828.
      Citations:    Fields:    Translation:Humans
    17. Diao K, Song J, Thall PF, McGinnis GJ, Boyce-Fappiano D, Amini B, Brown PD, Yeboa DN, Bishop AJ, Li J, Briere TM, Tatsui CE, Rhines LD, Chang EL, Ghia AJ. Low risk of radiation myelopathy with relaxed spinal cord dose constraints in de novo, single fraction spine stereotactic radiosurgery. Radiother Oncol. 2020 11; 152:49-55. PMID: 32745668.
      Citations:    Fields:    Translation:Humans
    18. Jiang L, Yan F, Thall PF, Huang X. Comparing Bayesian early stopping boundaries for phase II clinical trials. Pharm Stat. 2020 11; 19(6):928-939. PMID: 32720462.
      Citations: 1     Fields:    Translation:Humans
    19. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537). PMID: 32238575.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    20. Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal. 2021 Mar; 16(1):179-202. PMID: 34267857.
    21. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553. PMID: 32023374.
      Citations: 420     Fields:    Translation:HumansCellsCTClinical Trials
    22. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    23. Thall PF. Bayesian cancer clinical trial designs with subgroup-specific decisions. Contemp Clin Trials. 2020 03; 90:105860. PMID: 31678411.
      Citations:    Fields:    Translation:HumansCells
    24. Thall PF. Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials. JCO Precis Oncol. 2019; 3. PMID: 33015521.
      Citations: 2     Fields:    
    25. Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics. 2020 03; 76(1):304-315. PMID: 31273750.
      Citations: 2     Fields:    Translation:Humans
    26. Aparicio A, Thall P, Logothetis C. Radiotherapy for metastatic prostate cancer. Lancet. 2019 09 07; 394(10201):829-830. PMID: 31498098.
      Citations:    Fields:    Translation:Humans
    27. Chapple AG, Thall PF. Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III". Biometrics. 2019 06; 75(2):389-391. PMID: 31245839.
      Citations:    Fields:    
    28. Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. In Reply to Krishnatry and Manjali. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):468-469. PMID: 31047634.
      Citations:    Fields:    Translation:Humans
    29. Yan F, Thall P, Yuan Y. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med. 2019 05 09; 380(19):1876-1877. PMID: 31067386.
      Citations:    Fields:    Translation:Humans
    30. Lee J, Thall PF, Lin SH. Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer Patients. Ann Appl Stat. 2019 Mar; 13(1):221-247. PMID: 31681453.
    31. Boulet S, Ursino M, Thall P, Landi B, Lepère C, Pernot S, Burgun A, Taieb J, Zaanan A, Zohar S, Jannot AS. Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Stat Methods Med Res. 2020 02; 29(2):541-567. PMID: 30963815.
      Citations: 2     Fields:    Translation:Humans
    32. Chapple AG, Thall PF. A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III. Biometrics. 2019 06; 75(2):371-381. PMID: 30367457.
      Citations: 1     Fields:    
    33. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    34. Boulet S, Ursino M, Thall P, Jannot AS, Zohar S. Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. Stat Med. 2019 05 30; 38(12):2228-2247. PMID: 30672015.
      Citations: 3     Fields:    Translation:Humans
    35. Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):144-148. PMID: 30610915.
      Citations: 8     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    36. Xu Y, Thall PF, Hua W, Andersson BS. Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. J R Stat Soc Ser C Appl Stat. 2019 Apr; 68(3):809-828. PMID: 31467455.
    37. Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant. 2019 08; 54(8):1245-1253. PMID: 30532055.
      Citations: 2     Fields:    Translation:Humans
    38. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622. PMID: 30479692.
      Citations: 10     Fields:    
    39. Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. J Am Stat Assoc. 2018; 113(523):1255-1267. PMID: 30739965.
      Citations: 2     
    40. Chapple AG, Thall PF. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Pharm Stat. 2018 11; 17(6):734-749. PMID: 30112806.
      Citations: 1     Fields:    Translation:Humans
    41. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452. PMID: 30032678.
      Citations: 8     Fields:    Translation:Humans
    42. Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 09 01; 24(17):4098-4109. PMID: 29769208.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    43. Lee J, Thall PF, Rezvani K. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times. J R Stat Soc Ser C Appl Stat. 2019 Feb; 68(2):461-474. PMID: 31105345.
      Citations: 5     
    44. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609. PMID: 29501779.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    45. Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2018 03 01; 29(3):694-699. PMID: 29267863.
      Citations: 9     Fields:    Translation:Humans
    46. Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. 2018 09; 74(3):1095-1103. PMID: 29359314.
      Citations: 4     Fields:    Translation:Humans
    47. Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Stat Methods Med Res. 2019 02; 28(2):404-418. PMID: 28870123.
      Citations: 6     Fields:    Translation:Humans
    48. Thall PF, Mueller P, Xu Y, Guindani M. Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharm Stat. 2017 11; 16(6):414-423. PMID: 28677272.
      Citations: 1     Fields:    Translation:Humans
    49. Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc. 2017; 112:11-23. PMID: 28943681.
      Citations: 6     
    50. Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 06; 123(3):376-381. PMID: 28455153.
      Citations: 21     Fields:    Translation:Humans
    51. Chapple AG, Vannucci M, Thall PF, Lin S. Bayesian variable selection for a semi-competing risks model with three hazard functions. Comput Stat Data Anal. 2017 Aug; 112:170-185. PMID: 29033478.
      Citations: 3     
    52. Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clin Trials. 2017 Oct; 14(5):432-440. PMID: 28982263.
      Citations: 16     Fields:    Translation:Humans
    53. Morita S, Thall PF, Takeda K. A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. Pharm Stat. 2017 03; 16(2):143-156. PMID: 28111916.
      Citations: 3     Fields:    Translation:Humans
    54. Müller P, Xu Y, Thall PF. Clinical Trial Design as a Decision Problem. Appl Stoch Models Bus Ind. 2017 May-Jun; 33(3):296-301. PMID: 29200977.
      Citations: 5     
    55. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant. 2017 Apr; 52(4):580-587. PMID: 27991894.
      Citations: 19     Fields:    Translation:Humans
    56. Xu Y, Müller P, Wahed AS, Thall PF. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times. J Am Stat Assoc. 2016; 111(515):921-935. PMID: 28018015.
      Citations: 14     
    57. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 03; 31(3):697-704. PMID: 27654852.
      Citations: 38     Fields:    Translation:HumansCellsPHPublic Health
    58. He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol. 2016 10; 121(1):70-74. PMID: 27562616.
      Citations: 6     Fields:    Translation:Humans
    59. Xu Y, Thall PF, Müller P, Mehran RJ. A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling. Bayesian Anal. 2017; 12(3):639-652. PMID: 28959372.
      Citations: 3     
    60. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine?±?Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800. PMID: 27377901.
      Citations: 6     Fields:    Translation:Humans
    61. Thall PF, Nguyen HQ, Zinner RG. Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes. J R Stat Soc Ser C Appl Stat. 2017 01; 66(1):201-224. PMID: 28255183.
      Citations: 4     
    62. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405.
      Citations: 18     Fields:    Translation:Humans
    63. Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med. 2016 10 30; 35(24):4285-4305. PMID: 27189672.
      Citations: 7     Fields:    Translation:Humans
    64. Lee J, Thall PF, Ji Y, Müller P. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 2016 Apr; 17(2):304-19. PMID: 26553915.
      Citations: 2     Fields:    Translation:Humans
    65. Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat. 2016 02; 65(2):273-297. PMID: 27034510.
      Citations: 12     
    66. Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol. 2015 Oct; 125(1):133-41. PMID: 26255071.
      Citations: 9     Fields:    Translation:Humans
    67. Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 Oct 15; 121(20):3659-67. PMID: 26177983.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    68. Huang X, Choi S, Wang L, Thall PF. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Stat Med. 2015 Nov 20; 34(26):3424-43. PMID: 26095711.
      Citations: 6     Fields:    Translation:Humans
    69. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    70. Lee J, Thall PF, Ji Y, Müller P. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. J Am Stat Assoc. 2015 Jun 01; 110(510):711-722. PMID: 26366026.
      Citations: 15     
    71. Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015 Aug; 26(8):1621-8. PMID: 25979922.
      Citations: 29     Fields:    Translation:Humans
    72. Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1392-8. PMID: 25985919.
      Citations: 35     Fields:    Translation:Humans
    73. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946. PMID: 25867648.
      Citations: 13     Fields:    Translation:Humans
    74. Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26. PMID: 25695222.
      Citations:    Fields:    Translation:Humans
    75. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8. PMID: 25721897.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    76. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    77. Graziani R, Guindani M, Thall PF. Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome. Biometrics. 2015 Mar; 71(1):188-197. PMID: 25319212.
      Citations: 1     Fields:    Translation:Humans
    78. Wang L, Shen J, Thall PF. A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity Constraint. Stat Probab Lett. 2014 Oct 01; 93:126-133. PMID: 25071299.
      Citations: 4     
    79. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505. PMID: 25267759.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    80. Thall PF, Herrick RC, Nguyen HQ, Venier JJ, Norris JC. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials. 2014 Dec; 11(6):657-66. PMID: 25179541.
      Citations: 6     Fields:    Translation:Humans
    81. Thall PF, Nguyen HQ, Zohar S, Maton P. Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. J Am Stat Assoc. 2014 Sep 01; 109(507):931-943. PMID: 25368435.
      Citations: 5     
    82. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1139-44. PMID: 24727332.
      Citations: 10     Fields:    Translation:Humans
    83. Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. J Am Stat Assoc. 2014; 109(506):525-536. PMID: 25382884.
      Citations: 21     
    84. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    85. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics. 2013 Sep; 69(3):673-82. PMID: 23957592.
      Citations: 14     Fields:    Translation:Humans
    86. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8. PMID: 23872222.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    87. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003.
      Citations: 131     Fields:    Translation:Humans
    88. David E, Thall PF, Kalhor N, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Wei C, Mehran RJ. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg. 2013 Jun; 95(6):1872-7; discussion 1877. PMID: 23643547.
      Citations: 13     Fields:    Translation:Humans
    89. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. 2013 Sep; 48(9):1218-23. PMID: 23503529.
      Citations: 11     Fields:    Translation:HumansCells
    90. Wahed AS, Thall PF. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. J R Stat Soc Ser C Appl Stat. 2013 01; 62(1):67-83. PMID: 24014891.
      Citations: 11     
    91. Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80. PMID: 23220013.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    92. Morita S, Thall PF, Müller P. Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Anal. 2012 Sep; 7(3). PMID: 24175005.
      Citations: 8     
    93. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85. PMID: 22867894.
      Citations: 97     Fields:    Translation:Humans
    94. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013 Jan; 48(1):26-31. PMID: 22732703.
      Citations: 4     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    95. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc. 2012 Jun; 107(498):493-508. PMID: 22956855.
      Citations: 26     
    96. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. PMID: 22643322.
      Citations: 19     Fields:    Translation:Humans
    97. Thall PF, Nguyen HQ, Wang X, Wolff JE. A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. J Stat Plan Inference. 2012 Apr 01; 142(4):944-955. PMID: 22228921.
    98. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc. 2012; 107(498):518-520. PMID: 24489418.
      Citations: 2     
    99. Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. J R Stat Soc Ser C Appl Stat. 2012 01 01; 61(1):135-149. PMID: 22408277.
    100. Thall PF, Nguyen HQ. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat. 2012; 22(4):785-801. PMID: 22651115.
      Citations: 26     Fields:    Translation:Humans
    101. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012 Jul 15; 118(14):3549-55. PMID: 22086552.
      Citations: 19     Fields:    Translation:Humans
    102. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64. PMID: 21967975.
      Citations: 63     Fields:    Translation:Humans
    103. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15. PMID: 21887685.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    104. Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. Anticancer Res. 2011 Jun; 31(6):2265-9. PMID: 21737651.
      Citations: 1     Fields:    Translation:Humans
    105. Thall PF, Liu DD, Berrak SG, Wolff JE. Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies. Stat Med. 2011 Jul 10; 30(15):1777-94. PMID: 21590700.
      Citations: 1     Fields:    Translation:Humans
    106. Thall PF, Szabo A, Nguyen HQ, Amlie-Lefond CM, Zaidat OO. Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics. 2011 Dec; 67(4):1638-46. PMID: 21401568.
      Citations: 6     Fields:    Translation:Humans
    107. Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res. 2011 Jul; 31(7):539-44. PMID: 21323568.
      Citations: 1     Fields:    Translation:Humans
    108. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900. PMID: 20946966.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    109. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011 Mar; 17(3):412-20. PMID: 20674757.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    110. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Dec 01; 116(23):5420-31. PMID: 20672358.
      Citations: 132     Fields:    Translation:HumansCellsCTClinical Trials
    111. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20; 28(24):3851-7. PMID: 20625118.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    112. Morita S, Thall PF, Müller P. Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Stat Biosci. 2010 Jul 01; 2(1):1-17. PMID: 20668651.
      Citations: 8     
    113. Thall PF. Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials. Stat Sci. 2010 May; 25(2):227-244. PMID: 21318084.
      Citations: 7     
    114. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Feb 15; 116(4):814-21. PMID: 20052721.
      Citations: 7     Fields:    Translation:Humans
    115. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27; 88(8):1019-24. PMID: 19855248.
      Citations: 80     Fields:    Translation:HumansCells
    116. Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat. 2009 09 03; 59(1):19-34. PMID: 20390057.
      Citations: 3     
    117. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1431-8. PMID: 19822303.
      Citations: 21     Fields:    Translation:Humans
    118. Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics. 2010 Jun; 66(2):532-40. PMID: 19673865.
      Citations: 35     Fields:    Translation:Humans
    119. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol. 2009 Dec; 95(3):383-392. PMID: 19543851.
      Citations: 39     Fields:    Translation:Humans
    120. Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol. 2009 Jun; 21 Suppl 1:S11-5. PMID: 19561406.
      Citations: 6     Fields:    Translation:HumansAnimals
    121. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7. PMID: 19414678.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    122. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    123. Norman PH, Thall PF, Purugganan RV, Riedel BJ, Thakar DR, Rice DC, Huynh L, Qiao W, Wen S, Smythe WR. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer. 2009 Feb 15; 115(4):833-41. PMID: 19130460.
      Citations: 3     Fields:    Translation:Humans
    124. Thall PF. Discussion on "A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials" by Elena M. Buzaianu and Pinyuen Chen. Seq Anal. 2009 Jan 01; 28(1):41-43. PMID: 20622929.
    125. Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med. 2008 Nov 29; 27(27):5586-604. PMID: 18752257.
      Citations: 9     Fields:    Translation:Humans
    126. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87. PMID: 19012911.
      Citations: 13     Fields:    Translation:Humans
    127. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009 Apr; 16(4):910-9. PMID: 18953611.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    128. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 04; 99(9):1426-32. PMID: 18841158.
      Citations: 5     Fields:    Translation:HumansCells
    129. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    130. Whelan HT, Cook JD, Amlie-Lefond CM, Hovinga CA, Chan AK, Ichord RN, Deveber GA, Thall PF. Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke. 2008 Sep; 39(9):2627-36. PMID: 18617665.
      Citations: 4     Fields:    Translation:Humans
    131. Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med. 2008 Jul 10; 27(15):2802-15. PMID: 17948869.
      Citations: 13     Fields:    Translation:Humans
    132. Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Curr Opin Oncol. 2008 Jul; 20(4):407-11. PMID: 18525336.
      Citations: 5     Fields:    Translation:Humans
    133. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84. PMID: 18489993.
      Citations: 68     Fields:    Translation:HumansCellsCTClinical Trials
    134. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics. 2008 Dec; 64(4):1126-36. PMID: 18355387.
      Citations: 23     Fields:    Translation:Humans
    135. Thall PF. Some Geometric Methods for Constructing Decision Criteria Based On Two-Dimensional Parameters. J Stat Plan Inference. 2008; 138(2):516-527. PMID: 18617987.
      Citations: 1     
    136. Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics. 2008 Jul; 9(3):442-57. PMID: 18084008.
      Citations: 19     Fields:    Translation:Humans
    137. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 Nov 20; 26(26):4687-702. PMID: 17427204.
      Citations: 29     Fields:    Translation:Humans
    138. McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6727-34. PMID: 18006774.
      Citations: 11     Fields:    Translation:Humans
    139. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. PMID: 17989720.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    140. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate. 2007 Nov 01; 67(15):1677-85. PMID: 17879948.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    141. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007 Nov 07; 99(21):1613-22. PMID: 17971530.
      Citations: 27     Fields:    Translation:Humans
    142. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. PMID: 17908974.
      Citations: 46     Fields:    Translation:Humans
    143. Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Anal. 2008 Mar; 14(1):37-53. PMID: 17763973.
      Citations: 16     Fields:    Translation:Humans
    144. Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics. 2008 Jun; 64(2):595-602. PMID: 17764481.
      Citations: 43     Fields:    
    145. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007 Jul 01; 25(19):2755-63. PMID: 17602081.
      Citations: 226     Fields:    Translation:HumansCTClinical Trials
    146. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer. 2007 Mar; 43(5):859-66. PMID: 17306975.
      Citations: 56     Fields:    Translation:Humans
    147. Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials. 2007; 4(2):113-24. PMID: 17456511.
      Citations: 26     Fields:    Translation:Humans
    148. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61. PMID: 17029276.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    149. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer. 2006 Apr 01; 106(7):1617-23. PMID: 16518826.
      Citations: 10     Fields:    Translation:Humans
    150. Thall PF, Wooten LH, Shpall EJ. A geometric approach to comparing treatments for rapidly fatal diseases. Biometrics. 2006 Mar; 62(1):193-201. PMID: 16542246.
      Citations: 4     Fields:    Translation:Humans
    151. Thall PF, Estey EH, Markman M. Some ethical issues in phase II trials in acute leukemia. Clin Adv Hematol Oncol. 2006 Feb; 4(2):95. PMID: 16739255.
      Citations:    Fields:    Translation:Humans
    152. Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med. 2006 Jan 15; 25(1):55-70. PMID: 16025549.
      Citations: 19     Fields:    Translation:Humans
    153. Thall PF, Cook JD, Estey EH. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat. 2006; 16(5):623-38. PMID: 17037262.
      Citations: 18     Fields:    Translation:Humans
    154. Thall PF, Estey EH. Some ethical issues in phase II trials in acute leukemia. Clin Adv Hematol Oncol. 2005 Dec; 3(12):943-8. PMID: 16555436.
      Citations: 1     Fields:    Translation:Humans
    155. Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med. 2005 Jul 15; 24(13):1947-64. PMID: 15806621.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    156. Braun TM, Yuan Z, Thall PF. Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics. 2005 Jun; 61(2):335-43. PMID: 16011679.
      Citations: 11     Fields:    Translation:Humans
    157. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14. PMID: 15682071.
      Citations: 33     Fields:    Translation:Humans
    158. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials. 2005; 2(6):467-78. PMID: 16422307.
      Citations: 17     Fields:    Translation:Humans
    159. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004 Nov 15; 22(22):4567-74. PMID: 15542808.
      Citations: 34     Fields:    Translation:Humans
    160. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004 Sep; 60(3):684-93. PMID: 15339291.
      Citations: 117     Fields:    Translation:Humans
    161. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9. PMID: 15310776.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    162. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004 Aug 15; 22(16):3375-80. PMID: 15310783.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    163. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004 Jun; 33(12):1191-9. PMID: 15122310.
      Citations: 9     Fields:    Translation:Humans
    164. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76. PMID: 15131032.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    165. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64. PMID: 15073038.
      Citations: 132     Fields:    Translation:Humans
    166. Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant. 2003 Nov; 9(11):722-4. PMID: 14682302.
      Citations: 2     Fields:    Translation:Humans
    167. Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in Phase I oncology trials. Biometrics. 2003 Sep; 59(3):487-96. PMID: 14601749.
      Citations: 48     Fields:    Translation:Humans
    168. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9. PMID: 12842982.
      Citations: 5     Fields:    Translation:HumansCells
    169. Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer. 2003 May-Jun; 13(3):251-61. PMID: 12801254.
      Citations: 22     Fields:    Translation:Humans
    170. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. PMID: 12752098.
      Citations: 6     Fields:    Translation:Humans
    171. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med. 2003 Mar 15; 22(5):763-80. PMID: 12587104.
      Citations: 30     Fields:    Translation:Humans
    172. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 01; 21(5):878-83. PMID: 12610188.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    173. Shaw PH, Gilligan D, Wang XM, Thall PF, Corey SJ. Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system. Biol Blood Marrow Transplant. 2003 Mar; 9(3):151-6. PMID: 12652464.
      Citations: 3     Fields:    Translation:HumansCells
    174. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 01; 97(3):561-7. PMID: 12548597.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    175. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003 Jul 15; 102(2):442-8. PMID: 12560224.
      Citations: 24     Fields:    Translation:Humans
    176. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2003 Jan; 88(1):73-9. PMID: 12504632.
      Citations: 64     Fields:    Translation:HumansCells
    177. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002 Dec; 58(4):823-31. PMID: 12495136.
      Citations: 21     Fields:    Translation:HumansCells
    178. Thall PF. Ethical issues in oncology biostatistics. Stat Methods Med Res. 2002 Oct; 11(5):429-48. PMID: 12357588.
      Citations: 9     Fields:    Translation:Humans
    179. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8. PMID: 12229990.
      Citations: 9     Fields:    Translation:Humans
    180. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002 Aug 15; 95(4):758-65. PMID: 12209719.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    181. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80. PMID: 12118020.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    182. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9. PMID: 12036860.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    183. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002 Jun; 117(4):869-74. PMID: 12060122.
      Citations: 5     Fields:    Translation:HumansCells
    184. Cheung YK, Thall PF. Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics. 2002 Mar; 58(1):89-97. PMID: 11890331.
      Citations: 9     Fields:    Translation:Humans
    185. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85. PMID: 12374452.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    186. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001 Dec 15; 98(13):3575-83. PMID: 11739159.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    187. Stallard N, Thall PF. Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics. 2001 Dec; 57(4):1089-95. PMID: 11764248.
      Citations: 3     Fields:    Translation:Humans
    188. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73. PMID: 11745292.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    189. Thall PF, Sung HG, Choudhury A. Dose-finding based on feasibility and toxicity in T-cell infusion trials. Biometrics. 2001 Sep; 57(3):914-21. PMID: 11550945.
      Citations: 2     Fields:    Translation:HumansCells
    190. Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy. Stat Med. 2001 Apr 15; 20(7):1023-32. PMID: 11276033.
      Citations: 5     Fields:    Translation:Humans
    191. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    192. Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6. PMID: 10784623.
      Citations: 2     Fields:    Translation:HumansCells
    193. Thall PF, Millikan RE, Sung HG. Evaluating multiple treatment courses in clinical trials. Stat Med. 2000 Apr 30; 19(8):1011-28. PMID: 10790677.
      Citations: 55     Fields:    Translation:Humans
    194. Dougherty TB, Porche VH, Thall PF. Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology. 2000 Apr; 92(4):1010-6. PMID: 10754620.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    195. Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics. 2000 Mar; 56(1):213-9. PMID: 10783798.
      Citations: 3     Fields:    Translation:Humans
    196. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000 Jan 01; 95(1):72-7. PMID: 10607687.
      Citations: 19     Fields:    Translation:Humans
    197. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300. PMID: 10590370.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    198. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      Citations: 16     Fields:    Translation:HumansCells
    199. Stallard N, Thall PF, Whitehead J. Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics. 1999 Sep; 55(3):971-7. PMID: 11315037.
      Citations: 9     Fields:    Translation:Humans
    200. Thall PF, Cheng SC. Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. Biometrics. 1999 Sep; 55(3):746-53. PMID: 11315002.
      Citations: 2     Fields:    Translation:Humans
    201. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      Citations: 22     Fields:    Translation:Humans
    202. Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia. 1999 Jun; 13(6):850-4. PMID: 10360371.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    203. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69. PMID: 10363337.
      Citations: 11     Fields:    Translation:Humans
    204. Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81. PMID: 10373061.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    205. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84. PMID: 10194425.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    206. Thall PF, Estey EH, Sung HG. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs. 1999; 17(2):155-67. PMID: 10638486.
      Citations: 4     Fields:    Translation:Humans
    207. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
      Citations: 40     Fields:    Translation:HumansCells
    208. Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med. 1998 Sep; 158(3):876-84. PMID: 9731020.
      Citations: 26     Fields:    Translation:Humans
    209. Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma. 1998 Aug; 30(5-6):583-9. PMID: 9711920.
      Citations: 5     Fields:    Translation:HumansCells
    210. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med. 1998 Jul 30; 17(14):1563-80. PMID: 9699230.
      Citations: 23     Fields:    Translation:Humans
    211. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med. 1998 May 15; 17(9):999-1015. PMID: 9612887.
      Citations: 5     Fields:    Translation:Humans
    212. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res. 1998 Apr; 4(4):861-7. PMID: 9563879.
      Citations: 1     Fields:    Translation:HumansCells
    213. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998 Mar; 54(1):251-64. PMID: 9544520.
      Citations: 48     Fields:    Translation:Humans
    214. Staniswalis JG, Thall PF, Salch J. Semiparametric regression analysis for recurrent event interval counts. Biometrics. 1997 Dec; 53(4):1334-53. PMID: 9423253.
      Citations: 1     Fields:    Translation:Humans
    215. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997 Oct 15; 90(8):2969-77. PMID: 9376577.
      Citations: 31     Fields:    Translation:HumansCells
    216. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997 Oct; 11(10):1661-4. PMID: 9324286.
      Citations: 25     Fields:    Translation:Humans
    217. van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6. PMID: 9310192.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    218. Spector N, Pulcheri W, Nucci M, Maiolino A. Comparing an apple to a fruit salad. J Clin Oncol. 1997 Aug; 15(8):3021-2. PMID: 9256146.
      Citations:    Fields:    Translation:Humans
    219. O'Brien S, Thall PF, Siciliano MJ. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):259-76. PMID: 9376663.
      Citations: 2     Fields:    Translation:HumansCells
    220. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60. PMID: 9052911.
      Citations: 3     Fields:    Translation:Humans
    221. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997 Feb; 15(2):483-90. PMID: 9053469.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    222. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1997; 40 Suppl:S9-12. PMID: 9272127.
      Citations: 4     Fields:    Translation:Humans
    223. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51. PMID: 8986814.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    224. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 01; 87(9):3650-4. PMID: 8611689.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    225. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol. 1996 Jan; 14(1):296-303. PMID: 8558211.
      Citations: 20     Fields:    Translation:Humans
    226. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996 Jan; 27(1):65-73. PMID: 8699228.
      Citations: 118     Fields:    Translation:Humans
    227. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia. 1995 Oct; 9(10):1735-41. PMID: 7564518.
      Citations:    Fields:    Translation:Humans
    228. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1995 Sep 30; 33(2):357-64. PMID: 7673023.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    229. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995 Feb 28; 14(4):357-79. PMID: 7746977.
      Citations: 70     Fields:    Translation:Humans
    230. Thall PF, Simon RM. Recent developments in the design of phase II clinical trials. Cancer Treat Res. 1995; 75:49-71. PMID: 7640167.
      Citations: 3     Fields:    Translation:Humans
    231. Thall PF, Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials. 1994 Dec; 15(6):463-81. PMID: 7851108.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    232. Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Stat Med. 1994 Sep 15; 13(17):1727-36. PMID: 7997706.
      Citations: 21     Fields:    Translation:Humans
    233. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994 Jun; 50(2):337-49. PMID: 7980801.
      Citations: 47     Fields:    Translation:Humans
    234. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994 Apr; 12(4):671-8. PMID: 7512125.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    235. Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994 Mar 15-Apr 15; 13(5-7):417-29. PMID: 8023026.
      Citations: 10     Fields:    Translation:Humans
    236. Thall PF, Estey EH. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med. 1993 Jul 15; 12(13):1197-211. PMID: 8210822.
      Citations: 6     Fields:    Translation:Humans
    237. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992 May 01; 79(9):2246-55. PMID: 1571541.
      Citations: 8     Fields:    Translation:Humans
    238. Thall PF, Vail SC. Some covariance models for longitudinal count data with overdispersion. Biometrics. 1990 Sep; 46(3):657-71. PMID: 2242408.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    239. Thall PF, Simon R. Incorporating historical control data in planning phase II clinical trials. Stat Med. 1990 Mar; 9(3):215-28. PMID: 2188324.
      Citations: 15     Fields:    Translation:Humans
    240. Halperin M, Hamdy MI, Thall PF. Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring. Biometrics. 1989 Jun; 45(2):509-21. PMID: 2765635.
      Citations: 2     Fields:    Translation:Humans
    241. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989 Jun; 45(2):537-47. PMID: 2765637.
      Citations: 17     Fields:    Translation:Humans
    242. Thall PF, Simon R, Ellenberg SS, Shrager R. Optimal two-stage designs for clinical trials with binary response. Stat Med. 1988 May; 7(5):571-9. PMID: 3387716.
      Citations: 9     Fields:    
    243. Thall PF. Mixed Poisson likelihood regression models for longitudinal interval count data. Biometrics. 1988 Mar; 44(1):197-209. PMID: 3358988.
      Citations: 5     Fields:    Translation:Humans
    244. Thall PF, Lachin JM. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat Med. 1986 Jan-Feb; 5(1):73-83. PMID: 3515475.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    245. Estimating genomic category probabilities from fluorescent in situ hybridization counts with misclassification. Journal of the Royal Statistical Society. Series C: Applied Statistics. 45:431-446.
    246. Dose-Finding Based on Multiple Ordinal Toxicities in Phase I Oncology Trials. 243-258.
    247. Discussion on "a hybrid selection and testing procedure with curtailment for comparative clinical trials" by Elena M. Buzaianu and Pinyuen Chen. Sequential Analysis. 28:41-43.
    248. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia. Journal of the Royal Statistical Society. Series C: Applied Statistics. 62:67-83.
    249. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. Journal of the American Statistical Association. 107:493-508.
    250. Analysis of recurrent events based on random interval count data. Controlled Clinical Trials. 7:237.
    251. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. Journal of Thoracic Oncology. 10:518-526.
    252. A Bayesian hierarchical mixture model for platelet-derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. Journal of the Royal Statistical Society. Series C: Applied Statistics. 59:19-34.
    253. Two-stage selection and testing designs for comparative clinical trials. Biometrika. 75:303-310.
    254. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    255. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation.
    256. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.
    257. Evaluating the impact of prior assumptions in Bayesian biostatistics. Statistics in Biosciences. 2:1-17.
    258. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 17:304-319.
    259. Bayesian models and decision algorithms for complex early phase clinical trials. Statistical Science. 25:227-244.
    260. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. Journal of the Royal Statistical Society. Series C: Applied Statistics. 61:135-149.
    261. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiotherapy and Oncology. 121:70-74.
    262. A modified adaptive Lasso for identifying interactions in the Cox model with the heredity constraint. Statistics and Probability Letters. 93:126-133.
    263. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times. Journal of the American Statistical Association. 111:921-950.
    264. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    265. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia.
    266. Reply from authors re. European Urology. 62:1022.
    267. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors. Journal of Neuro-Oncology. 125:133-141.
    268. A theorem on regular infinitely divisible cox processes. Stochastic Processes and their Applications. 16:205-210.
    269. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1392-1398.
    270. Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival. Journal of the Royal Statistical Society. Series C: Applied Statistics. 65:273-297.
    271. Optimal two-stage designs for clinical trials with binary response. Controlled Clinical Trials. 9:252.
    272. Letter to the editors. Clinical Advances in Hematology and Oncology. 4:95.
    273. Variable selection in regression via repeated data splitting. Journal of Computational and Graphical Statistics. 6:416-434.
    275. Score tests in the two-way layout of counts. Communications in Statistics - Theory and Methods. 21:3017-3036.
    276. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. 35:4285-4305.
    277. Huber-sense robust M-estimation of a scale parameter, with application to the exponential distribution. Journal of the American Statistical Association. 74:147-152.
    278. Using Both Efficacy and Toxicity for Dose-Finding. 275-285.
    279. Analysis of recurrent events. Journal of the American Statistical Association. 83:339-347.
    280. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351)). Proceedings of the National Academy of Sciences of the United States of America. 94:5495.
    281. Selecting therapeutic strategies based on efficacy and death in multicourse clinical trials. Journal of the American Statistical Association. 97:29-39.
    282. Comments on 'Continuous Bayesian adaptive randomization based on event times with covariates' [4]. Statistics in Medicine. 26:3052-3054.
    283. Test-Based Variable Selection Via Cross-Validation. Journal of Computational and Graphical Statistics. 1:41-61.
    284. A Two-Stage Design for Dose-Finding with Two Agents. 259-274.
    285. A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity. Journal of Statistical Planning and Inference. 142:944-955.
    286. Response. Journal of the National Cancer Institute. 100:682-683.
    287. Bayesian guidelines for phase II clinical trial design and analysis. Controlled Clinical Trials. 13:377.
    288. Journal of the American Statistical Association. 109:525-536.
    289. Statistical controversies in clinical research. Annals of Oncology. 26:1621-1628.
    290. Some geometric methods for constructing decision criteria based on two-dimensional parameters. Journal of Statistical Planning and Inference. 138:516-527.
    291. Rejoinder. Journal of the American Statistical Association. 111:948-950.
    292. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. Journal of the American Statistical Association. 110:711-722.
    293. Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. Journal of the American Statistical Association. 109:931-943.
    294. Rejoinder. Journal of the American Statistical Association. 107:518-520.
    295. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Statistics in Medicine. 34:3424-3443.
    296. An explanation of generalized profile likelihoods. Statistics and Computing. 11:293-298.
    297. Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    298. Biology of Blood and Marrow Transplantation. 22:1792-1800.
    299. Prior effective sample size in conditionally independent hierarchical models. Bayesian Analysis. 7:591-614.
    300. Clinical trial design as a decision problem. Applied Stochastic Models in Business and Industry.
    301. On the structure of regular infinitely divisible point processes. Stochastic Processes and their Applications. 6:87-94.
    302. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial. Journal of the American Statistical Association. 99:26-35.
    THALL's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (608)
    Co-Authors (227)
    Similar People (60)
    Same Department Expand Description